Health ASX Health Stocks: Little Green Pharma closing in on first over-the-counter CBD product in Australia
ASX Health Stocks: Zelira to test its own drug against a Big Pharma’s multi-billion dollar revenue star
Cannabis stock, Zelira Therapeutics (ASX:ZLD), announced that it has completed the enrolment for its Diabetic Nerve Pain Drug Trial. Read More The post ASX Health Stocks: Zelira to test its own drug against a Big Pharma’s multi-billion dollar revenue star appeared first on Stockhead.
- Little Green Pharma gets ethics approval to commence Phase 3 trial
- EMVision has commenced a clinical trial
Little Green Pharma to start Phase 3 trial
Cannabis companyhas secured Human Research Ethics Approval for its Phase III SleepWell Study.
The results of this clinical trial will support LGP’s proposed Australian Schedule 3 CBD product registration for stress reduction and improved quality of sleep.
Schedule 3 (Pharmacist Only) products can be sold to Australian consumers over-the-counter without prescription.
ASX Health Stocks: Pot stock BOD’s Phase 1 results; Paradigm and Impedimed shake up exec teams
Cannabis stock Bod Australia (ASX:BOD) announced positive results from Phase 1 clinical trial evaluating Bod’s ECS BioAbsorb Softgel Capsule. Read More The post ASX Health Stocks: Pot stock BOD’s Phase 1 results; Paradigm and Impedimed shake up exec teams appeared first on Stockhead.
There are currently no OTC CBD products available in the Australian market.
Right now, CBD products cannot legally be bought in Australia without a prescription from a doctor because these products are considered Prescription Medicines.
And according to various studies, insomnia is a huge market.
The estimated global market for insomnia is $5.4 billion by 2023, with the Pharmacist Only CBD market in Australia expected to reach $250 million and over 2 million consumers at market maturity.
The condition is known to be triggered by stressful events as well as genetic factors.
Little Green Pharma share price today:
EMVision commences brain scanner trial
has commenced a clinical trial to show that EMV’s portable brain scanner can provide crucial insights to enable clinicians to make critical decisions earlier at the point-of-care.
Celebrity facialist reveals at-home skincare devices that don't work
The celebrity facialist behind Pip Edwards and Bambi Northwood Blyth's radiantly youthful complexions has revealed which at-home skincare devices are worth the fanfare.Ingrid Seaburn treats the faces of Australia's rich and famous at her upscale Bondi salon.
Stage 1 of the trial commences with 30 healthy volunteers, followed by Stage 2 with up to 150 Acute Stroke/Stroke mimic patients.
The company has also completed user training at Liverpool Hospital, receiving the administrative “green light” activation.
Both enrolment and scanning are now underway at the Hospital.
“The training process was smooth and easy across individuals from a range of clinical fields of expertise,” said EMVision CEO, Dr Ron Weinberger.
“And it was completed in less than a day and the team is excited to undertake the clinical trial.”
Back in October, EMV announced that it was about to commence a multi-centre clinical trial following an ethics committee approval.
EM Vision is seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke.
The technology is the result of over 10 years of development by researchers at the University of Queensland.
EMV share price today:
The postappeared first on .
ASX Small Caps Lunch Wrap: Who else is looking for a unicorn this morning? .
The ASX started well but hit lunchtime looking pretty sluggish, Partiot Lithium took off with a bang and Downer's still Read More The post ASX Small Caps Lunch Wrap: Who else is looking for a unicorn this morning? appeared first on Stockhead.